Technology
Genetic medicines such as CAR-T, gene replacement and CRISPR gene editing therapies have achieved transformative clinical outcomes. Despite successes, the high complexity and cost have significantly limited patient access to current ex vivo therapies.
At Tiva Bio, we envision a future where genetic medicines can be precisely and efficiently delivered to targeted cell types in vivo at a fraction of the cost of ex vivo cell and gene therapies.
LNP and tLNP formulation
Customizable LNP formulation
From 10 µg to grams — the same platform scales from early screening through GMP-ready production.
A diverse selection of targeting binders
Cell-specific binding moieties, such as Fab or nanobody, precisely conjugated to the LNP that enables preferential delivery to specific cell types.
Versatile Conjugation Chemistry
We have established various conjugation technologies to enable site-specific binder conjugation, ensuring product homogeneity, batch-to-batch consistency, and scalable manufacturing.
Platforms
Manufacturing and Analytical Platforms
Seamless LNP manufacturing from Discovery to large-scale GMP production
End-to-end analytical platform: from chemistry to functionality
Scalable conjugation processes
GMP-ready raw materials, consumables, and reagents
Multiple Mixing Methods Available
T-Mixer
